Skip to main content
SpringerLink
Log in

Biological Response Modifiers: Current Status and Prospects as Anti-Cancer Agents

  • Chapter
Basic and Clinical Tumor Immunology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 14))

Abstract

‘Biological response modifier’ (BRM) is a term recently coined to include the many agents and approaches to the treatment of cancer whose mechanism of action involves modulation of the individual’s own biological responses. Although activation of host responses, particularly the host-immune response, has been the goal of therapists for many generations, recent technologic advances have improved our understanding of biological responses making manipulation of them for therapy a practical goal. In particular, tremendous strides have been made in the last three to five years in molecular biology with respect to nucleic acid sequencing and translation, protein sequencing and synthesis, isolation and purification of biological products, mass cell culture, and ‘genetic engineering’ of eukaryotic genes in bacteria, yeasts and into eukaryotic cells. The advent of these ‘new technologies’ has led the way to a greater understanding of biologics which may exist in exceedingly minute quantities but have tremendous amplifying powers with respect to their effect on host responses. Historically, ‘activity’ has been detected in many biological preparations, but the isolation and purification of the active factor has been fraught with many difficulties. The technology is now available for large-scale production of biologics, the isolation and purification of these products, and eventually their production by genetic engineering or by chemical synthesis. Because of these recent advances, biological response modifying therapy is now a reality and our understanding of BRMs will likely be of great value in understanding cancer biology and improving cancer therapeutics in this decade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Oldham RK: Biological Response Modifiers Program. J Biol Resp Mod 1: 81–100, 1982.

    Google Scholar 

  2. Mathe G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, Vassal F: Active immunotherapy for acute lymphoblastic leukemia. Lancet 1: 697–699, 1969.

    Article  PubMed  CAS  Google Scholar 

  3. Powles RL, Crowther D, Bateman CJT, Beard MEJ, McElwain TJ, Russel J, Lister TA, Whitehouse JMA, Wrigley PFM, Pike M, Alexander P, Hamilton Fairley G: Immunotherapy for acute myelogenous leukaemia. Br J Cancer 28: 365–376, 1973.

    Article  PubMed  CAS  Google Scholar 

  4. Gutterman JU, Hersh EM, Rodriguez V, McCredie KB, Mavligit G, Reed R, Burgess MA, Smith T, Gehan E, Bodey GP, Freireich EJ: Chemoimmunotherapy of adult acute leukaemia: Prolongation of remission in myeloblasts leukaemia with B.C.G. Lancet 2: 1405–1409, 1974.

    Article  PubMed  CAS  Google Scholar 

  5. Vogler WR, Chang YK: Prolonging remission in myeloblasts leukaemia by Tice-Strain Bacillus Calmette-Guerin. Lancet 2: 128–131, 1974.

    Article  PubMed  CAS  Google Scholar 

  6. Foon KA, Smalley RV, Gale RP: The role of immunotherapy in acute myelogenous leukemia Arch Int Med. In press, 1983.

    Google Scholar 

  7. Terry WD, Rosenberg SA (eds), Immunotherapy of human cancer. New York: Excerpta Medica, 1982.

    Google Scholar 

  8. Jones SE: Chemoimmunotherapy of malignant lymphoma. In: Immunotherapy of human cancer, Terry WD, Rosenberg SA (eds). New York: Excerpta Medica, 1982, pp 55–60.

    Google Scholar 

  9. Albert DS, Mason NL, O’Toole R, Neff J, Hilgers R, Carlin D, Moon TE: A randomized trial of doxorubicin and cyclophosphamide plus BCG versus doxorubicin and cyclophosphamide therapy of advanced ovarian cancer. In: Immunotherapy of human cancer, Terry WD, Rosenberg SA (eds). New York: Excerpta Medica, 1982, pp 343–350.

    Google Scholar 

  10. Morton DL, Eilber FR, Malmgren RA: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68: 158–164, 1970.

    PubMed  CAS  Google Scholar 

  11. Nathanson L, Schoenfeld D, Regelson W, Colsky J, Mittelman A: Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer 43: 1630–1635, 1979.

    Article  PubMed  CAS  Google Scholar 

  12. Mastrangelo MJ, Bellet RE, Laucius JF, Berkelhammer J: In: Oncologic medicine, AJ Sutnick and PF Engstrom (eds). Baltimore: University Park Press, 1976, pp 71–93.

    Google Scholar 

  13. Rapp HJ, Churchill Jr. WH, Kronman BS, Rolley RT, Hammond WG, Borsos T: Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma: Pathology and formulation of ascites variant. JNCI 41: 1–11, 1968.

    PubMed  CAS  Google Scholar 

  14. Zbar B, Canti G, Ashley MP, Rapp HJ, Hunter JT, Ribi E: Eradication by immunization with mycobacterial vaccines and tumor cells of microscopic metastases remaining after surgery. Ca Res 39: 1597–1603, 1979.

    CAS  Google Scholar 

  15. Hunter JT, Ashley MP, Rapp HJ, Sukumar S, Zbar B: Pulmonary Metastases in guinea pigs as a consequence of dermal implantation of line-10 tumor cells. Ca Imm Immunother 11: 39–44, 1981.

    Google Scholar 

  16. Hunter JT, Ashley MP, Sukumar S, Sugimoto T, Zbar B, Rapp HJ, Yarkoni E: Treatment by limited surgery and specific immunization of guinea pigs with stage II experimental cancer. J Exp Med 154: 253–261, 1981.

    Article  PubMed  CAS  Google Scholar 

  17. Yarkoni E, Rapp HJ: Regression by active specific immunotherapy of established dermal tumor transplants and lymph node metastases in guinea pigs. Inf and Imm 31: 514–516, 1981.

    CAS  Google Scholar 

  18. Yarkoni E, Ashley MP, Zbar B, Sugimoto T, Rapp HJ: Eradication by active specific immunotherapy of established tumor transplants and microscopic lymph node metastases. Ca Res 42: 2544–2546, 1982.

    CAS  Google Scholar 

  19. Ribi E, Cantrell J, Schwartzman S, Parker R: BCG cell wall skeleton, P3, MDP and other microbial components-Structure activity studies in animal models. In: Augmenting agents in cancer therapy, Hersch EM, Chirigos MA, Mastrangelo MJ (eds). New York: Raven Press, 1981, pp 15–32.

    Google Scholar 

  20. McLaughlin CA, Strain SM, Bickel WD, Goren MB, Azuma I, Milner K, Cantrell JL, Ribi E: Regression of line–10 hepatocellular carcinomas following treatment with water-soluble, microbial extracts combined with trehalose or arabinose mycolates. Ca Imm Immunother 4: 61–68, 1978.

    Google Scholar 

  21. Cantrell JL, Ribi E, McLaughlin CA: Passive transfer of tumor immunity with spleen cells from guinea pigs cured of hepatocarcinoma by nonspecific immunotherapy. Ca Imm Immunother 4: 21–28, 1978.

    Google Scholar 

  22. McLaughlin CA, Bickel WD, Kyle JS, Ribi E: Synergistic tumor regressive activity observed following treatment of line–10 hepatocellular carcinomas with deproteinized BCG cell walls and mutant salmonella typhimurium glycolipid. Ca Imm Immunother 5: 45–52, 1978.

    Google Scholar 

  23. Kelly MT, McLaughlin CA, Ribi EE: Eradication of microscopic lymph node metastases of the guinea lig line–10 tumor after intradermal injection of endotoxin plus mycobacterial components. Ca Imm Immunother 4: 29–32, 1978.

    Google Scholar 

  24. Vosika GJ, Schmidtke J, Goldman A, Ribi E, Parker R, Gray GR: Local and systemic immunotherapy of human cancer with mycobacterial cell wall skeleton and trehalose dimycolate (P3). In: Augmenting agents in cancer therapy, Hersh EM, Chirigos MA, Mastrangelo M (eds). New York: Raven Press, 1981, pp 33–51.

    Google Scholar 

  25. Richman SP, Gutterman JU, Hersh EM, Ribi EE: Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P3. Ca Imm Immunother 5: 41–44, 1978.

    Google Scholar 

  26. Peters LC, Brandhorst JS, Hanna, Jr. MG: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Ca Res 39: 1353–1360, 1979.

    CAS  Google Scholar 

  27. Hanna, Jr. MG, Brandhorst JS, Peters LC: Active specific immunotherapy of residual micrometastasis. Ca Imm Immunother 7: 165–173, 1979.

    Google Scholar 

  28. Peters LC, Hanna, Jr. MG: The specific immunotherapy of established micrometastasis: Effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. JNCI 64: 1521–1525, 1980.

    PubMed  CAS  Google Scholar 

  29. Hoover Jr. HC, Peters LC, Brandhorst JS, Hanna Jr. MG: Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model. J Surg Res 30: 409–415, 1981.

    Article  PubMed  Google Scholar 

  30. Key Me, Hanna Jr. MG: Mechanics of action BCG-tumor cell vaccines in the generation of systemic tumor immunity: I. Synergism between BCG and line 10 tumor cells in the induction of an inflammatory response. JNCI 67: 853–861, 1981.

    PubMed  CAS  Google Scholar 

  31. Key ME, Hanna Jr. MG: Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity: II. Influence of the local inflammatory response on immune reactivity. JNCI 67: 863–869, 1981.

    PubMed  CAS  Google Scholar 

  32. Hanna Jr. MG, Bucana C: Active specific immunotherapy of residual micrometastasis: The acute and chronic inflammatory response in induction of tumor immunity by BCG-tumor cell immunization. J Ret Soc 26: 439–452, 1979.

    Google Scholar 

  33. Key ME, Hoyer, L, Bucana C, Hanna Jr. MG: Mechanisms of macrophage-mediated tumor cytolysis. In: Mechanisms of cell mediated cytotoxicity, Clark WR, Goldstein P (eds). New York: Plenum, 1982, pp 265–310.

    Google Scholar 

  34. Hanna Jr. MG, Peters LC: Morphological and functional aspects of active specific immunotherapy of established pulmonary metastases in guinea pigs. Ca Res 41: 4001–4009, 1981.

    Google Scholar 

  35. Hanna Jr. MG, Key ME: Immunotherpay of metastases enhances subsequent chemotherapy. Science, 217: 367–369, 1982.

    Article  PubMed  Google Scholar 

  36. Galli SJ, Bast Jr. RC, Bast BS, Isomura T, Zbar B, Rapp HJ, Dvorak HF: Bystander suppression of tumor growth: Evidence that specific targets and bystanders are damaged by injury to a common microvasculature. J Imm 129: 890–899, 1982.

    CAS  Google Scholar 

  37. Dye ES, North RJ, Mills CD: Mechanisms of anti-tumor action of corynebacterium parvum. J Exp Med 154: 609–620, 1981.

    Article  PubMed  CAS  Google Scholar 

  38. Taniguchi T, Mantei N, Schwarzstein M, Nagata S, Muramatsu M, Weissmann C: Human leukocyte and fibroblast interferons are structurally related. Nature 285: 547–549, 1980.

    Article  PubMed  CAS  Google Scholar 

  39. Yip YK, Pang RHL, Urban C, Vilcek J: Partial purification of human gamma (immune) interferon. Proc NAS (USA) 78: 1601–1605, 1981.

    Article  CAS  Google Scholar 

  40. De Mayer–Guignard J, Tovey MG, Gresser 1, De Maeyer E: Purification of mouse interferon by sequential affinity chromatography on poly(U)-and antibody-agarose columns. Nature 271: 622–625, 1978.

    Article  Google Scholar 

  41. Taylor–Papadimitriou J: Effects of interferons on cell growth and function. In: Interferon 2, Gressor I (ed). London: Academic Press, 1980, pp 13–46.

    Google Scholar 

  42. Borden EC, Ball LA: Interferon: Biochemical cell growth inhibitory and immunological effects. In: Progress in hematology, Vol XII, Brown, ER (ed). New York: Grune amf; Stratton, 1981, pp 299–339.

    Google Scholar 

  43. Gresser I, Tovey MG: Antitumor effects of interferon. Biochem. amf; Biophys Acta 516: 231–247, 1978.

    CAS  Google Scholar 

  44. Gresser I, Coppey J, Brouty-Boye DF, Falcoff E: Interferon and murine leukemia: III. Efficacy of interferon preparation administered after inoculation friend virus. Nature 215: 174–175, 1967.

    Article  PubMed  CAS  Google Scholar 

  45. Gresser I, Bergman L, DeThe G, Broutz-Boye DF, Coppey J, Falcoff E: Interferon and murine leukemia: V. Effect of interferon preparations on the evolution of Rauscher disease in mice. JNCI 41: 505–509, 1968.

    PubMed  CAS  Google Scholar 

  46. Rossi GB, Marchegiani M, Matarese GP, Gresser I: Brief communication: Inhibitory effect of interferon on multiplication of friend leukemia cells in vivo. JNCI, 54: 993–996, 1975.

    PubMed  CAS  Google Scholar 

  47. Bart RS, Porzio NR, Kopf AW, Vilcek JT, Cheng EH, Farcet Y: Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Ca Res 40: 614–619, 1980.

    CAS  Google Scholar 

  48. Ratner L, Nordlund JJ, Lengyel P: Interferon as an inhibitor of cell growth: Studies with mouse melanoma cells. Proc Soc Exp Bio Med 163: 267–272, 1980.

    CAS  Google Scholar 

  49. Gresser I, Coppey J, Bourali C: Interferon and murine leukemia: IV. Effect of interferon preparations on the lymphoid leukemia of AKR mice. JNCI 43: 1083–1089, 1969.

    PubMed  CAS  Google Scholar 

  50. Came PE, Moore DH: Inhibition of spontaneous mammary carcinoma of mice by treatment with interferon and poly I: C. Proc Soc Exp Biol Med 137: 304–305, 1971.

    PubMed  CAS  Google Scholar 

  51. Gresser I, Maury C, Tovey M: Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice. Int J Cancer 17: 647–651, 1976.

    Article  PubMed  CAS  Google Scholar 

  52. Kassel RL, Pascal RR, Vas A: Interferon-mediated oncolysis in spontaneous murine leukemia. JNCI 48: 1155–1159, 1972.

    PubMed  CAS  Google Scholar 

  53. Gresser I, Maury C, Brouty-Boye D: Mechanism of the antitumor effect of interferon in mice. Nature 239: 167–168, 1972.

    Article  PubMed  CAS  Google Scholar 

  54. Gresser I: Commentary: On the varied biologic effects of interferon. Cell Imm 34: 406–415, 1977.

    Article  CAS  Google Scholar 

  55. Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H: Interferon therapy in myelomatosis. Lancet 1: 245–247, 1979.

    Article  PubMed  CAS  Google Scholar 

  56. Einhorn N, Cantell K, Einhorn S, Strander H: Human leukocyte interferon therapy for advanced ovarian carcinoma. Am J Clin Oncol (CCT) 5: 167–172, 1982.

    Article  CAS  Google Scholar 

  57. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Int Med 93: 399–406, 1980.

    PubMed  CAS  Google Scholar 

  58. Freedman R, Wharton JT, Rutledge F: Human leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma: (A preliminary report). Proc AACR 22: 372, 1981.

    Google Scholar 

  59. Einhorn S, Strander H: Interferon therapy for neoplastic diseases in man: In vitro and in vivo studies. Adv Exp Med Biol 110: 159–174, 1978.

    PubMed  CAS  Google Scholar 

  60. Borden EC, Holland JF, Dao TL, Gutterman JU, Wiener L, Chang YC, Patel J: Leukocyte-derived interferon (alpha) in human breast carcinoma. Ann Int Med 97: 1–10, 1982.

    PubMed  CAS  Google Scholar 

  61. Louie AC, Gallagher JG, Skora K, Levy R, Rosenberg SA, Merigan TC: Follow-up observations on the effect of human leukocyte interferon in non-Hodkin’s lymphoma. Blood 58: 712–718, 1981.

    PubMed  CAS  Google Scholar 

  62. Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg SA: Preliminary observations on the effect of human leukocyte interferon in non–Hodgkin’s lymphoma. NEJM 299: 1449–1453, 1978.

    Article  PubMed  CAS  Google Scholar 

  63. Finter NB, Fantes KH: The purity and safety of interferons prepared for clinical use: The case of lymphoblastoid interferon. In: Interferon 2 Gresser I (ed). London: Academic Press, 1980, pp 65–80.

    Google Scholar 

  64. Fantes KH, Allen G: Specific activity of pure human interferons and a non-biological method for estimating the purity of highly purified interferon preparations. J Interferon Res 1: 465–472, 1981.

    Article  PubMed  CAS  Google Scholar 

  65. Goeddel DV, Yelverton E, Ullrich A, Heyneker HL, Miozzari G, Holmes W, Seeburg PH, Dull T, May L, Stebbing N, Crea R, Maeda S, McCandliss R, Sloma A, Tabor JM, Gross M, Familletti PC, Pestka S: Human leukocyte interferon produced by E. coli is biologically active. Nature 287: 411–416, 1980.

    CAS  Google Scholar 

  66. Streuli M, Nagata S, Weissmann C: At least three human type alpha interferons: Structure of alpha-2. Science 209: 1343–1347, 1980.

    Article  PubMed  CAS  Google Scholar 

  67. Neefe JR, Streevalsan T, Bash JA: Phase I trial of immunomodulatory activities of human leukocyte interferon in advanced cancer patients. Proc AACR 23: 245, 1982.

    Google Scholar 

  68. Bash JA, Woody JN, Neefe JR: Phase I trial of immunomodulating activities of human leukemic interferon in advanced cancer patients. In: NK cells and other natural effector cells, Herberman RB (ed). New York: Academic Press, 1982, pp 1273–1278.

    Google Scholar 

  69. Merigan TC: Human interferon as a therapeutic in cancer. Proc 13th Annual Int Ca Cong, Seattle; p 82, 1982.

    Google Scholar 

  70. Frei E, Personal communication.

    Google Scholar 

  71. Bash JA, Teitelbaum D, Neefe JR: Immunomodulatory activities of human leukocyte interferon in advanced cancer patients. J Biol Resp Mod. In press, 1983.

    Google Scholar 

  72. Sarna G, Figlin R, Bryson Y, Mauritzon N, Cline M: Phase I trial of human lymphoblastoid interferon (HuLyINF) administered intermittently. Proc ASCO 1: 39, 1982.

    Google Scholar 

  73. Laszlo J, Huang A, Brenckman W, Koren H, Cianciolo G, Buckley Jr CE, Cox E, Cash-dollar W, Metzgar R, Lucas Jr VS, Jeffs C, Dorenkamp S: Immunopharmacology of human lymphoblastoid interferon (IF) in man. Proc AACR 23: 245, 1982.

    Google Scholar 

  74. Laszlo J, Huang A, Brenckman W, Koren H, Cianciolo G, Buckley III CE, Cox E, Cash-dollar W, Metzgar R: Immune modulation and toxicity produced in a phase I study of human lymphoblastoid interferon (IF). Proc 13th Annual Int Ca Cong, Seattle, WA, p 235, 1982.

    Google Scholar 

  75. Knost J, Sherwin S, Foon K, Abrams P, Ochs J, Williams R, Maluish A, Oldham R: A phase I trial of lymphoblastoid interferon using a 6 hour intravenous infusion. Proc ASCO, 1: 35, 1982.

    Google Scholar 

  76. Koren H, Brandt C, Laszlo J: Modulation of natural killer (NK) cell activity induced by human lymphoblastoid interferon (IFN) In vivo and in vitro. Proc 13th Annual Int Ca Cong, Seattle, WA, p 377, 1982.

    Google Scholar 

  77. Gutterman J, Fein S, Quesada J, Horning S, Levine J, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowska Z: Recombinznt leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Int Med 96: 549–556, 1982.

    PubMed  CAS  Google Scholar 

  78. Sherwin S, Knost J, Fein S, Abrams P. Foon K, Ochs J, Schoenberger C, Maluish A, Oldham R: A multiple dose phase I trial of recombinant leukocyte A interferon on a 3 times weekly schedule. JAMA 248: 2461–2466, 1982.

    Article  PubMed  CAS  Google Scholar 

  79. Fein S, Bernhardt L, Grossbard E, Franco S, Bigley J, Dziewanowska Z: The Biologic activity of recombinant leukocyte A interferon. Proc 13th Annual Int Ca Cong, Seattle, WA, p 173, 1982.

    Google Scholar 

  80. Rudnick S, Schering Corporation: Personal Communication.

    Google Scholar 

  81. Maluish A, Ortaldo J, Sherwin S, Leavitt R, Strong D, Fein S, Wiernik P, Oldham R, Herberman R: Immunological monitoring of patients receiving recombinant leukocyte A interferon. Proc ASCO, 1: 39, 1982.

    Google Scholar 

  82. Sherwin S, Mayer D, Ochs J, Abrams P, Knost J, Foon K, Fein S, Oldham R: Recombinant leukocyte A interferon in advanced breast cancer: Results of a preliminary phase II efficacy trial. Ann Int Med 98: 598–602, 1983.

    PubMed  CAS  Google Scholar 

  83. Hawkins M, Krown S, Borden E, Real F, Krim M, Cunningham-Rundles S, Oettgen H,Fox R, Stock C, Rauscher F: American Cancer Society phase I trial of human interferon beta (IFN–β). Proc AACR, 23: 246, 1982.

    Google Scholar 

  84. Sherwin S, Oldham R: BRMP, NCI, Frederick, MD.

    Google Scholar 

  85. Gutterman J: MD Anderson Hospital and Tumor Institute, Houston, Tx.

    Google Scholar 

  86. Levy H, Stephen E, Harrington D, Engel K, Riley F, Lvovsky E: Polynucleotides in the treatment of disease. In: Augmenting agents in cancer therapy, Hersh E, Chirigos M, Mastrangelo M (eds). New York: Raven Press, 1981, pp 135–150.

    Google Scholar 

  87. Levy H, Bear G, Baron S, Buckler C, Gibbs C, Iadarola M, London W, Rice J: A modified polyriboinosinic–polyribocytidylic acid complex that induces interferon in primates. J Inf Dis 132: 434–439, 1975.

    Article  CAS  Google Scholar 

  88. Lampson G, Field A, Tytell A, Hilleman M: Poly I:C/Poly-L-Lysine: Potent inducer of interferons in primates. J Interferon Res 1: 539–549, 1981.

    Article  PubMed  CAS  Google Scholar 

  89. Levine A, Sivulich M. Wiernik P, Levy H; Initial Clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [Poly(ICLC)], a highly effective interferon inducer. Ca Res 39: 1645–1650, 1979.

    CAS  Google Scholar 

  90. Levine A, Levy H: Phase I/II trials of poly IC stabilized with poly-L-lysine. Ca Trt Rep 62: 1907–1913, 1978.

    CAS  Google Scholar 

  91. Levine A, Durie B, Lampkin B, Leventhal B, Levy H: Poly (ICLC): Interferon induction, toxicity, and clinical efficacy in leukemia, lymphoma, solid tumors, Myeloma, and laryngeal papillomatosis. In: Augmenting agents in cancer therapy, Hersh E, Chirigos M, Mastrangelo M (eds). New York: Raven Press, 1981, p 151–164.

    Google Scholar 

  92. Krown S, Kerr D, Stewart II W, Pollack M, Cunningham-Rundles S, Hirshaut Y, Pinsky C, Levy H, Oettgen H: Phase I trial of poly ICLC in patients with advanced cancer. In: Augmenting agents in cancer therapy, Hersh E, Chirigos M, Mastrangelo M (eds). New York: Raven Press, 1981, pp 165–176.

    Google Scholar 

  93. 93.Champney K, Levine D, Levy H, Lerner M; Modified polyriboinosinic-polyribocytidylic acid complex: Sustained interferonemia and its physiological associates in humans. Inf and Imm 25: 831–837, 1979.

    Google Scholar 

  94. Engel WK, Cuneo RA, Levy HB: Polyinosinic-polycytidylic acid treatment of neuropathy. Lancet 1: 503–504, 1978.

    Article  PubMed  CAS  Google Scholar 

  95. Lampkin B, Levine AS, Levy H, Krivit W, Hammond D: Phase II trial of poly (ICLC) (An interferon (IF) inducer) in the treatment of children with acute leukemia (AL). Proc ASCO 1: 123, 1982.

    Google Scholar 

  96. Herberman RB, Reid J, Maluish A: Personal communication.

    Google Scholar 

  97. Thurman G, Marshall, G, Low T, Goldstein A: Recent developments in the classification and bioassay of thymosin polypeptides. In:Cell biology and immunology of leukocyte function, Quastrei MR (ed). New York: Academic Press, 1979, pp 189–199.

    Google Scholar 

  98. Wara D, Goldstein A, Doyle N, Ammann A: Thymosin activity in patients with cellular immunodeficiency. NEJM 292: 70–74, 1975.

    Article  PubMed  CAS  Google Scholar 

  99. Goldstein A, Wara D, Amman A, Sakai H, Harris N, Thurman G, Hooper J, Cohen G, Goldman A, Constanzi J, McDaniel M: First clinical trial with thymosin: Reconstitution of T-cell in patients with cellular immunodeficiency diseases. Trans Proc 7: 681–686, 1975.

    Google Scholar 

  100. Wara D, Ammann A: Thymosin treatment of children with primary immunodeficiency disease. Trans Proc 10: 203–209, 1978.

    CAS  Google Scholar 

  101. Wara D, Barrett D, Ammann A, Cowan M: In vitro and in vivo enhancement of mixed lymphocyte culture reactivity by thymosin in patients with primary immunodeficiency disease. J Pediat 97: 66–71, 1980.

    Article  PubMed  Google Scholar 

  102. Costanzi J, Gagliano R, Loukas D, Delaney F, Sakai H, Harris N, Thurman G, Goldstein A: The effect of thymosin on patients with disseminated malignancies: A phase I study. Cancer 40: 14–1977.

    Google Scholar 

  103. Costanzi J, Harris N, Goldstein A: Thymosin in patients with disseminated solid tumors: Phase I and II results. In: Immune modulation and control of neoplasia by adjuvant therapy, Chirigos M (ed). New York: Raven Press, 1978, pp 373–380.

    Google Scholar 

  104. Schafer L, Gutterman J, Hersh E, Mavligit G, Dandridge K, Cohen G, Goldstein A: Partial Restoration by in vivo thymosin of E-rossettes and delayed-type-hypersensitivity reactions in immunodeficient cancer patients. Ca Imm Immunother 1: 259, 1976.

    Google Scholar 

  105. Cohen M, Chretien P, Ihde D, Fossieck Jr. BE, Makuck R, Bunn Jr PA, Johnston AV, Shackney SE, Matthews MJ, Zpson SD, Kenady DE, Minna JD: Thymosin fraction V and intensive combination chemotherapy. JAMA 241: 1813–1815, 1979.

    Article  PubMed  CAS  Google Scholar 

  106. Wara W, Neely M, Ammann A, Wara D: Biologic modification of immunologic parameters in head and neck cancer patients with thymosin fraction V. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, Goldstein, A, Chirigos, M (eds). New York: Raven Press, 1981, pp 257–262.

    Google Scholar 

  107. Pinsky C, Wittes R: Personal communication.

    Google Scholar 

  108. Zatz M, Moshe G, Seals C, Goldstein A: Effects of combined cyclophosphamide and thymosin treatment on tumor growth and host survival in mice bearing a syngeneic tumor. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, Goldstein A, Chirigos M (eds). New York: Raven Press, 1981, pp 249–256.

    Google Scholar 

  109. Low T, Thurman G, McAdoo M, McClure J, Rossio J, Naylor P. Goldstein A: The chemistry and biology of thymosin: I. Isolation, characterization and biological activities of thymosin a\ and polypeptide from calf thymus. J Biol Chem, 254: 981–985, 1979.

    PubMed  CAS  Google Scholar 

  110. Dillman R, Beauregard J, Zavanelli M, Halliburton B, Royston I: Phase I trials of thymosin fraction 5 (TF5) and thymosin alpha-1 (TA1) and assessment of immunologic response. Proc ASCO 1: 42, 1982.

    Google Scholar 

  111. Fabrega R, Pinsky C, Braun Jr D, Chung T, Krown S, Oettgen H: Phase I trial of thymosin fraction 5 in cancer patients. Proc AACR 23: 126, 1982.

    Google Scholar 

  112. Wara W, Wara D, Neely M, Carter S: Phase I trial of thymosin fraction V in advanced malignancies. Preliminary NCOG Report. Presented at the Internal Symp on Immunomodulators, Montpelier, France, 1982.

    Google Scholar 

  113. Fefer A, Wright P, Goldberg R: Personal communication.

    Google Scholar 

  114. Schulof R, McClure J, Goldstein A: Thymosin al following mediastinal irradiation: An immunorestorative trial in patients with localized non-small cell lung cancer. Proc ASCO 1: 34, 1982.

    Google Scholar 

  115. Rosenberg SA, Terry WD: Passive immunotherapy of cancer in animals and man. Adv Ca Res, 25: 323–388, 1977.

    Article  CAS  Google Scholar 

  116. Bernstein ID, Tam MR, Nowinski RC: Mouse leukemia: Therapy with monoclonal antibodies against a thymus differentiation antigen. Science, 207: 68–69, 1980.

    Article  PubMed  CAS  Google Scholar 

  117. Bernstein ID, Nowinski RC: Monoclonal antibody treatment of transplanted and spontaneous murine leukemia. In: Hybridomas in cancer diagnosis and treatment, Mitchell MS, Oettgen HF (eds). New York: Raven Press, 1982, pp 97–112.

    Google Scholar 

  118. Kirch ME, Hammerling U: Immunotherapy of murine leukemias by monoclonal antibody: I. Effect of passively administered antibody on growth of transplanted tumor cells. J Imm 127: 805–810, 1981.

    CAS  Google Scholar 

  119. Royston I, Majda J, Baird SM, Meserve BL, Griffiths JC: Monoclonal antibody specific for human T lymphocytes: Identification of normal and malignant T cells. Blood 54 (Suppl 1): 106 A, 1979.

    Google Scholar 

  120. Engleman EG, Warnke R, Rox RI, Dilley J, Benike CJ, Levy R: Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc NAS (USA) 78: 1791–1795, 1981.

    Article  CAS  Google Scholar 

  121. Wang CY, Good RA, Ammirati P, Dymbort G, Evans RL: Identification of p69, 71 complex expressed on human T cells sharing determinants with B-type chronic lymphatic leukemic cells. J Exp Med 151: 1539–1544, 1980.

    Article  PubMed  CAS  Google Scholar 

  122. Martin PJ, Hansen J A, Siadak AW, Nowinski RC: Monoclonal antibodies recognizing normal human T lymphocytes and malignant human B lymphocytes: A comparative study. J Imm 127: 1920–1923, 1981.

    CAS  Google Scholar 

  123. Dillman RO, Shawler DL, Sobol RE, Collins HA, Beauregard JC, Wormsley SB, Royston I: Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59: 1036–1045, 1982.

    PubMed  CAS  Google Scholar 

  124. Miller RA, Levy R: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2: 226–230, 1981.

    Article  PubMed  CAS  Google Scholar 

  125. Miller RA, Maloney DG, McKillop J, Levy R: In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58: 78–86, 1981.

    PubMed  CAS  Google Scholar 

  126. Lynch RG, Rohrer JW, Odermatt B, Gebel HM, Autry JR, Hoover RG: Immunoregula-tion of murine myeloma cell growth and differentiation: A monoclonal model of B cell differentiation. Imm Rev 48: 45–80, 1979.

    Article  CAS  Google Scholar 

  127. Geha RS: Current concepts in immunology: Regulation of the immune response by antiidiotype interactions. NEJM 305: 25–28, 1981.

    Article  PubMed  CAS  Google Scholar 

  128. Stevenson GT, Stevenson FK: Antibody to a molecularly–defined antigen confined to a tumour cell surface. Nature 254: 714–716, 1975.

    Article  PubMed  CAS  Google Scholar 

  129. Hough DW, Eady RP, Hamblin TJ, Stevenson RF, Stevenson GT: Anti–idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes. J Exp Med, 144: 960–969, 1976.

    Article  PubMed  CAS  Google Scholar 

  130. Lanier LL, Babcock GF, Raybourne RB, Arnold LW, Warner NL, Haughton G: Mechanism of B cell lymphoma with passive xenogeneic anti-idiotype serum. J Imm 125: 1730–1736, 1980.

    CAS  Google Scholar 

  131. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti–idiotype antibody. NEJM 306: 517–523, 1982.

    Article  PubMed  CAS  Google Scholar 

  132. Lynch R: Immunoregulation of malignant lymphoma. NEJM 306: 543–544, 1982.

    Article  PubMed  CAS  Google Scholar 

  133. Oldham RK, Bernhard MI, Key M, Peters LC, Brandhorst J, Hanna MG, Foon KA: Monoclonal antibody serotherapy of solid tumors: A guinea pig model II. In vivo studies. Proc 13th Annual Int Ca Cong, Seattle, WA, pp. 585, 1982.

    Google Scholar 

  134. Herlyn D, Herlyn M, Steplewski Z, Koprowski H: Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Imm 9:657–659,

    Google Scholar 

  135. Herlyn D, Steplewski Z, Merlyn M, Koprowski H: Inhibition of growth of colorectal carcinoma in nude mice by-onoclonal antibody. Ca Res 40: 717–721, 1980.

    CAS  Google Scholar 

  136. Herlyn D, Koprowski H: Monoclonal anticolon carcinoma antibodies in complement–dependent cytotoxicity. Int J Ca 27: 27: 769–774, 1981.

    Article  CAS  Google Scholar 

  137. Sears HF, Herlyn M: Ex vivo perfusion of tumor–containing colon with monoclonal antibody. J. Surg Res 31: 145–50, 1981.

    Article  PubMed  CAS  Google Scholar 

  138. Herlyn D, Koprowski H: IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc NAS(USA) 79: 4751–4765, 1982.

    Article  Google Scholar 

  139. Langlois AJ, Matthews T, Roloson GJ, Thiel HJ, Colling JJ, Bolognesi DP: Immunologic control of the ascites form of murine adenocarcinoma 755 V: Antibody–directed macrophages mediate tumor cell destruction. J Imm 126: 2337–2341, 1981.

    CAS  Google Scholar 

  140. Sears HF, Mattis J, Herlyn D, Hayry P, Atkinson B, Ernst C, Steplewski Z, Koprowski H: Phase–I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1: 762–765, 1982.

    Article  PubMed  CAS  Google Scholar 

  141. Greaves MF, Brown G, Rapson NT, Lister TA: Antisera to acute lymphoblastic leukemia cells. Clin Imm Immunopath 4: 67–76, 1975.

    Article  CAS  Google Scholar 

  142. Ritz J, Nadler LM, Bahn AK, Notis-McConarty J, Pesando JM, Schlossman SF: Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood 58: 648–652, 1981.

    PubMed  CAS  Google Scholar 

  143. Pesando JM, Ritz J, Levine H, Terhorst C, Lazarus H, Schlossman SF: Human leukemia–Associzted antigen: Relation to a family of surface glycoproteins. J Imm 124:2794–2799,

    Google Scholar 

  144. Ritz J, Pesando JM, Sallan SE, Calvell LA, Notis-McConarty J, Rosenthal P, Schlossman SF. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58: 141–152, 1981.

    PubMed  CAS  Google Scholar 

  145. Ritz J, Sallan SE, Bast RC, Lipton JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schlossman SF: Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia following in vitro treatment with J5 monoclonal antibody and complement. Lancet 2: 60–63, 1982.

    Article  PubMed  CAS  Google Scholar 

  146. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF: Utilization of monoclonal antibodies in the diagnosis and treatment of acute lymphoblastic leukemia. Proc 13th Annual Int Ca Cong, Seattle, WA p 9, 1982.

    Google Scholar 

  147. Neville DM, Youle RJ: Monoclonal antibody-ricin or ricin A chain hybrids: Kinetic analysis of cell killing for tumor therapy. Imm Rev 62: 135–151, 1981.

    Google Scholar 

  148. Gilliland DG, Steplewski Z, Collier RF, Mitchell KF, Chang TH, Koprowski H: Antibody–directed cytotoxic agents: Use of monoclonal antibody to direct the action to toxin A chains to colorectal carcinoma cells. Proc NAS(USA) 77: 4539–4543, 1980.

    Article  CAS  Google Scholar 

  149. Mizusawa E, Dahlman HL, Bennett SJ, Goldenberg DM, Hawthorne, MF: Neutron–capture therapy of human cancer: In vitro results on the preparation of boron–labeled antibodies to carcinoembryonic antigen. Proc NAS(USA) 79: 3011–3014, 1982.

    Article  CAS  Google Scholar 

  150. Hurwitz E, Maron R, Bernstein A, Wilchek M, Sila M, Arnon R: The effect in vivo of chemotherapeutic drug-antibody conjugates in two murine experimental tumor systems. Int J Ca 21: 747–755, 1978.

    Article  CAS  Google Scholar 

  151. Jerrels TR, Dean JH, Richardson GL, McCoy JL, Herberman RB: Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients. JNCI 61: 1001–1009, 1978.

    Google Scholar 

  152. Broder S, Waldmann TA: The suppressor-cell network in cancer. NEJM 299: 1281–1284. 1978.

    Article  PubMed  CAS  Google Scholar 

  153. Broder S, Waldmann TA: The suppressor-cell network in cancer. NEJM 299: 1335–1341, 1978.

    Article  PubMed  CAS  Google Scholar 

  154. Kripke ML: Immunologic aspects of UV carcinogenesis. In: Trends in photobiology, Helene C, Charlier M, Montensy-Garostier T, Laustriat G (eds). New York; Plenum, 1982, pp 235–242.

    Google Scholar 

  155. Perry LL, Greene MI: T cell subset interactions in the regulation of syngeneic tumor immunity. Fed Proc 40: 39–41, 1981.

    PubMed  CAS  Google Scholar 

  156. Enker WE, Jacobitz JL: In vivo splenic irradiation eradicates suppressor T cells causing the regression and inhibition of established tumor. Int J Ca 25: 819–825, 1980.

    Article  CAS  Google Scholar 

  157. Reinherz EL, Kung PC, Goldstein G, Schlossman SF: Separation of functional subsets of human T cells by a monocloncal antibody. Proc NAS(USA) 76: 4061–4065, 1979.

    Article  CAS  Google Scholar 

  158. Evans RL, Wall DW, Platsoucar CD, Segal FP, Fiking SM, Testa CM. Good RA: Thymus dependent membrane antigens in man: Inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen. Proc NAS(USA) 78: 544–548, 1981.

    Article  CAS  Google Scholar 

  159. Foon K, Bernhard M, Oldham R: Monoclonal antibody therapy: Assessment by anima! tumor models. J Biol Resp Mod. In press, 1982.

    Google Scholar 

  160. Oldham R: Monoclonal antibodies as anticancer agents. In: Proc Symp BRM in Hum Oncol and Immun, Friedman H. New York: Plenum Press. In press, 1983.

    Google Scholar 

  161. Gery I, Gershon RK, Waksman BH: Potentiation of the T-lymphocytes response to mitogens: The responding cell. J Exp Med 136: 128–138, 1972.

    Article  PubMed  CAS  Google Scholar 

  162. Mizel SB, Ben–Zvi A: Studies on the role of lymphocyte-activating factor (interleukin 1) in antigen–induced lymph node lymphocyte proliferation. Cell Imm 54: 382–389, 1980.

    Article  CAS  Google Scholar 

  163. Farrar WL, Mizel SB, Farrar JJ: Participation of lymphocyte activating factor (interleukin 1) in the induction of cytotoxic T cell responses. J Imm 124: 1371–1377, 1980.

    CAS  Google Scholar 

  164. Oppenheim JJ, Stadler BM, Siragania RP, Mage M, Mathieson B: Lymphokines: Their role in lymphocyte responses-Properties of interleukin 1. Fed Proc, 41: 257–262, 1982.

    PubMed  CAS  Google Scholar 

  165. Ruscetti FW, Gallo RC: Human T-lymphocytes growth factor: Regulation of growth and function of T lymphocytes. Blood, 57: 379–394, 1981.

    PubMed  CAS  Google Scholar 

  166. Mier J, Gallo RC: The characterization of human T-cell growth factor and its role in the proliferation of malignant T-cells. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, Goldstein A and Chirigos A (eds). New Yrok: Raven Press, 1981, pp 33–48.

    Google Scholar 

  167. Gallo RC: Control of T-cell proliferation. Proc 13th Annual Ca Cong, Seattle WA, p431, 1982

    Google Scholar 

  168. Mizel SB: Purification to homogeneity of interleukin 1. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, AL Goldstein and MA Chirigos (eds). New York: Raven Press, 1981, pp 15–20.

    Google Scholar 

  169. Lachman LB, George IV. FW, Metzgar RS: Human interleukins 1 and 2: Purification and characterization. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, AL Goldstein and MA Chirigos (eds). New York: Raven Press, 1981, pp 21–32.

    Google Scholar 

  170. Gillis S, Mochizuki D, Conlon PJ, Hefeneidee SH: Biochemical and biological characterization of murine and human interleukien 2. Proc 13th Annual Int Ca Cong, Seattle, WA, p 236, 1982.

    Google Scholar 

  171. Gillis S: New reagents for interleukin 2 production and detection. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, Goldstein AL and Chirigos MA (eds). New York: Raven Press, 1981, pp 57–68.

    Google Scholar 

  172. Das SK, Stanley ER, Guilbert LJ, Forman LW: Human colony-stimulating factor (CSF–1) radioimmunoassay, resolution of 3 sub-classes of human colony-stimulating factors. Blood 58: 630–641, 1981.

    PubMed  CAS  Google Scholar 

  173. Ihle JN, Keller J, Lee JC, Farrar WL, Hapel AJ: Purification and biological properties of interleukin 3. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, Goldstein AL and Chirigos MA (eds). New York: Raven Press, 1981, 77–94.

    Google Scholar 

  174. Farrar JJ, Hilfiker ML: Antigen–nonspecific helper factors in the antibody response. Fed Proc, 41: 263–268, 1982.

    PubMed  CAS  Google Scholar 

  175. Howard M, Kessler S, Chused T, Paul WE: Long-term culture of normal mouse B lymphocytes. Proc. NAS(USA) 78: 5788–5792, 1981.

    Article  CAS  Google Scholar 

  176. Dumonde DC, Pulley MS, Hamblin AS, Singh AK, Southcott BM, CTConnel D, Paradinas FJ, Robinson MRG, Rigby CC, Den Hollander F, Scheims A, Verbeil H, Van Vhet E: Short term and long term administration of lymphoblastoid cell line lymphokine (LCL–LK) to patients with advanced cancer. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, Goldstein AL, Chirigos MA (eds). New York: Raven Press, 1981, pp 301–318.

    Google Scholar 

  177. Papermaster BW, Gilliland CD, McEntire JE, Rodes NE, Dunn PA: In vivo biological studies with lymphoblastoid lymphokines. In: Lymphokines and thymic hormones: Their potential utilization in cancer therapeutics, Goldstein AL, Chirigos MA (eds). New York: Raven Press, 1981, pp 289–300.

    Google Scholar 

  178. Fidler I, Berendt M, Oldham R: The rationale for and design of a screening procedure for the assessment of biological response modifiers for cancer treatment. J Biol Resp Mod 1: 15–26, 1982.

    Google Scholar 

  179. Stolfi R, Martin D: Therapeutic activity of maleic anhydride-vinyl ether copolymers against spontaneous antochtonous murine mammary tumors. Ca Trt Rep 62: 1791–1796, 1978.

    CAS  Google Scholar 

  180. Morahan P, Barnes D, Munson A: Relationship of molecular weight to antiviral and antitumor activities and toxic effects of MVE polyicons. Ca Trt Rep 62: 1797–1805, 1978.

    CAS  Google Scholar 

  181. Dean J, Padarathsingh M, Keys L: Response of murine leukemia to combined BCNU-MVE in in vitro growth inhibition assay. Ca Trt Rep 62: 1807–1816, 1978.

    CAS  Google Scholar 

  182. Mohr S, Chirigos M, Fuhrman F, Pryor J: Pyran copolymer as an effective adjuvant to chemotherapy against a murine leukemia solid tumor. Ca Res 35: 3750–3754, 1975.

    CAS  Google Scholar 

  183. Mohr S, Chirigos M, Smith G, Fuhrman F: Specific potentiation of LI210 vaccine by pyran copolymer. Ca Res 36: 2035–2039, 1976.

    CAS  Google Scholar 

  184. Chirigos M, Mastrangelo M: Immunorestoration by Chemicals. In: Immunochemical approaches to cancer therapeutics, Mihich E (ed). Wiley-Interscience 1982, pp 193–230.

    Google Scholar 

  185. Barnes D, Morahan P, Loveless S, Munson A: The effects of maleic anhydride-divinyl ether (MVE) copolymers on hepatic microsomal mixed-function oxides and other biological activities. J Pharm Exp Ther 208: 392–396, 1978.

    Google Scholar 

  186. Bartocci A, Papademetriou V, Chirigos M: Enhanced macrophage and natural killer cell tumor activity by various molecular weight maleic anhydride-divinyl ether. J Immuno-pharmacaol 2: 149–154, 1979.

    Google Scholar 

  187. Djeu J, Heinbaugh J, Horden H, Herberman R: Augmentation of mouse natural killer cell antitumor activity by interferon and interferon inducers. J Imm 122: 175–179, 1979.

    CAS  Google Scholar 

  188. Santonni A, Pucceti P, Riccardi C, Herberman R, Bonmasser E: Augmentation of natural killer cell activity by pyran copolymer in mice. Int J Ca 24: 656–660, 1979.

    Article  Google Scholar 

  189. Rosenblum M, Powell M, Hersh E: Phase I study of MVE-2 therapy in human cancer. Proc ASCO 1: 37, 1982.

    Google Scholar 

  190. Rinehart J, Wilson H, Neidhart J: Phase I evaluation of MVE-II in man. Proc ASCO 1: 37, 1982.

    Google Scholar 

  191. Forbes J, Luck A, Greco A: MVE–2: Phase I study and evaluation of biological response. Proc AACR 23: 134, 1982.

    Google Scholar 

  192. Wiener R: Personal communication.

    Google Scholar 

  193. Bicker U: Aziridine dyes: Preclinal and clinical studies. In: Current progress in cancer research and therapy, Hersh E, Chirigos M, Mastrangelo M, (eds). New York: Raven Press, 1981, pp 523–538.

    Google Scholar 

  194. Bicker U: Immunomodulating effects of BM 12.531 in animals and tolerance in man. Ca Trt Rep 62: 1987–1996, 1978.

    CAS  Google Scholar 

  195. Stylos WA, Chirigos MA, Papademetriou V, Lauer L: The immunomodulatory effect of BM 12531 (Azimexon) on normal and tumored mice: In vitro and in vivo studies. J Immunopharmacol 2: 113–120, 1980.

    Article  PubMed  CAS  Google Scholar 

  196. Bicker V, Heboid G, Ziegler AE, Maus W: Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by BM 12.531. Exp Pathol 15:49–55,

    Google Scholar 

  197. Matter A: The effects of muramyldipeptide (MDP) in cell-mediated immunity: A comparison between in vitro and in vivo systems. Ca Imm Immunother 6: 201–210, 1979.

    CAS  Google Scholar 

  198. Taniyama T, Horden H: Direct augmentation of cytolytic acivity of tumor derived macrophages and macrophage cell lines by muramyl dipeptide. Cell Imm 48: 369–374, 1979.

    Article  CAS  Google Scholar 

  199. Tenu J, Lederer G, Petit J: Stimulation of thymocyte mitogenic protein secretion and of cytostatic activity of mouse peritoneal macrophages by trehalose dimycolate and muramyl dipeptide. Eur J Imm 10: 647–653, 1980.

    Article  CAS  Google Scholar 

  200. Tanaka A, Nagoa S, Nagao R, Kotani S, Shiba T, Kusumoto S: Stimulation of the reticu-loendothelial system of mice by muramyl dipeptide. Inf amf; Imm 24: 302–307, 1979.

    CAS  Google Scholar 

  201. Nagao S, Tanaka A, Yamamoto Y, Koga T, Onoue K, Shiba T, Kusomoto K, Kotani S: Inhibition of macrophage migration by muramyl peptides. Inf amf; Imm 24:308–312,

    Google Scholar 

  202. Wahl S, Wahl L, MacCarthy J, Chedid L, Mergenhagen S: Macrophage activation by mycobacterial water soluable compounds and synthetic muramyl dipeptide. J Imm 122: 2226–2231, 1979.

    CAS  Google Scholar 

  203. Fidler I, Soue S, Fogler W, Barnes Z: Eradication of spontaneous metastases and activation of alvelolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc NAS (USA) 78: 1680–1684, 1981.

    Article  CAS  Google Scholar 

  204. Fidler I, Soue S, Fogler W, Smith D, Braun D, Tarcsey L, Gisler R, and Schroit A: Efficacy of Liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricical properties of alveolar macrophages in vivo. J Biol Resp Mod 1: 43–55, 1982.

    CAS  Google Scholar 

  205. Najjar VA: Biochemistry and Physiology of Tuftsin-Thr-Lys-Pro-Arg. In: The reticuloen-dothelial system, Sbarra S and Strauss R (eds). New York: Plenum Pub. Corp., 1980, pp 45–71.

    Google Scholar 

  206. Catane R, Schlonger S, Gottlieb P, Halpern J, Treves A, Fuks Z, Friedkin M: Toxicology and antitumor activity of tuftsin in mice. Proc AACR 22: 371, 1981.

    Google Scholar 

  207. Nishioka K, Amoscato AA, Babcock GA: Tuftsin: A hormone like tetrapeptide with antimicrobial and antitumor activities. Life Sci 28: 1081–1090, 1981.

    Article  PubMed  CAS  Google Scholar 

  208. Najjar VA, Chandhurri M, Konopincka D, Beck B, Layne P, Lineharr L: Tuftsin (Thr-Lys-Pro-Ang) a physiological activator of phagocytic cells: A possible role in cancer therapy. In: Augmenting agents in cancer therapy, Hersh E, Chirigos M, Mastrangelo M, (eds). New York: Raven Press, 1981, pp 459–478.

    Google Scholar 

  209. Florentin I, Bruley-Rosset M, Kiger N, Umbach J, Winternitz F, Mathe G: In vivo stimulation by tuftsin. Ca Imm Immunother 5: 211–216, 1978.

    CAS  Google Scholar 

  210. Phillips J, Babcock G, Nishioka K: Tuftsin a naturally occurring immunopotentiating Factor I: In vitro enhancement of murine natural cell-mediated immunity. J Imm 126: 915–921, 1981.

    CAS  Google Scholar 

  211. Chirhara G: The antitumor polysaccharide lentinan: An overview. In: Manipulation of host defense mechanisms, Aoki T, Urushizaki I, Tsubura E (eds) New York: Excerpta Medica, 1981, pp 1–16.

    Google Scholar 

  212. Aoki T, Miyakoski H, Horikawa Y, Yoshimaru Y: Staphage lysate and lentinan as immu-nomodulators and/or immunoptentiators in clinical and experimental systems. In: Progress in cancer research and therapy, Hersh E, Chirigos M, Mastrangelo M (eds). New York: Raven Press, 1981, pp 101–112.

    Google Scholar 

  213. Chihara G, Maeda YY, Hamuro J, Sasaki T, Fukuoka F: Inhibition of mouse sarcoma 180 by polysaccharides from Lentius edodes (Berk). Sing. Nature, 222: 687–688, 1969.

    Article  CAS  Google Scholar 

  214. Chihara G, Hamura J, Maeda YY, Arai Y, Fukuoka F: Fractionation and purification of the polysaccharides with marked antitumor activity, especially Lentinan, from Lentinus edodes (Berk.) Sing, (an edible mushroom). Ca Res 30: 2776–2781, 1970.

    CAS  Google Scholar 

  215. Maeda YY, Hamuro J, Yamada YO, Ishimura K, Chichara G: The nature of immunopo–tentiation by the antitimour polysaccharide Lentinan and the signiflancance of biogenic amines in its action. In: Immunopotentiation, Wolstenholme GEW, Knight J (eds). Ciba Found. Symposium, new series 18. Amsterdam: Elsevier, Excerpta-Medica, North-Holland, 1973, pp 259–268.

    Google Scholar 

  216. Zakany J, Chirhara G, Fachet J: Effect of Lentinan on tumour growth in murine allogenic and syngeneic hosts. Int J Ca 25: 371–376, 1980.

    Article  CAS  Google Scholar 

  217. Zakany J, Chihara G, Fachet J: Effect of Lentinan on the production of migration inhibitory factor induced by syngeneic tumor in mice. Int J Ca 26: 783–788, 1980.

    Article  CAS  Google Scholar 

  218. Hamada C: Inhibitory effects of lentinan on the tumorigenesis of adeno-virus type 12 in mice. In: Manipulation of host defense mechanisms, Aoki T, Urushizaki I, Tsubura E (eds). New York: Excerpta Medica, 1981, pp 76–87.

    Google Scholar 

  219. Maeda YY, Chihara G: Lentinan, a new immune-accelerator of cell-mediated responses. Nature 229: 634, 1971.

    Article  PubMed  CAS  Google Scholar 

  220. Maeda YY, Hamuro J, Chihara G: The mechanism of antitumour polysaccharides: The effect of antilymphocyte serum on the antitumour activity of Lentinan. Int J Ca 8: 41–46, 1971.

    Article  CAS  Google Scholar 

  221. Maeda YY, Chihara G: The effects of neonatal thymectomy on the antitumour activity of Lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune responses. Int J Ca 11: 153–161, 1973.

    Article  CAS  Google Scholar 

  222. Maeda YY, Chihara G: Periodical consideration of establishment of antitumour action in host and activation of peritoneal exudate cell by Lentinan. Gann Jap J Ca Res 64: 351–357, 1973.

    CAS  Google Scholar 

  223. Dresser DW, Phillips JM:The orientation of the adjuvant activities of Salmonella typhosa lipopolysaccharide and Lentinan. Imm 27: 895–902, 1974.

    CAS  Google Scholar 

  224. Dennart G, Tucker D: Antitumor polysaccharide Lentinan, a T cell adjuvant. JNCI 51: 1727–1729, 1973.

    Google Scholar 

  225. Hamuro J, Rollinghoff M, Wagner H: Induction of cytotoxic peritoneal exudate cells by T cell immune adjuvants of the B(l,3)-glucan-type Lentinan and its analogues. Imm 39: 551–559, 1980.

    CAS  Google Scholar 

  226. Hamuro J, Rollinghoff M, Wagner H: B(l,3)–glucan–mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Ca Res 38: 3080–3085, 1978.

    CAS  Google Scholar 

  227. Hamuro J, Wagner H, Rollinghoff M: B(l,3)-glucans as a probe for T cell specific immune adjuvants: II. Enhanced in vitro generation of cytotoxic T lymphocytes. Cell Imm 38: 328–335, 1978.

    Article  CAS  Google Scholar 

  228. Sendo F, Siji K, Fuyama S, Wztabe S, Arai S: Augmentation of natural cell mediated cytotoxicity by administration of lentinan in mice. In: Manipulation of host defense mechanisms, Aoki T, Urushizaki I, Tsubura E (eds). New York: Excerpta Medica, 1981, pp 178–187.

    Google Scholar 

  229. Herberman R, Nunn–Hargrove M: Augmentation of natural killer (NK) cell activity by lentinan. In: Manipulation of host defense mechanisms, Aoki T, Urushizaki I, Tsubura E (eds). New York: Excerpta Medica, 1981, pp 188–189.

    Google Scholar 

  230. Akiyama Y, Kashima S, Hayami T, Izawa M, Mitsugi K, Hamuro K: Immunological characteristics of antitumor polysaccharides, lentinan and its analogs as immune adjuvants. In: Manipulation of host defense mechanisms, Aoki T, Urushizaki I, Tsubura E (eds). Excerpta Medica, 1981, pp 222–243.

    Google Scholar 

  231. Falk R, Makowka L, Nossal N, Falk J, Fields J, Asculai S: Modulation of the immune response and control of tumour spread by a new synthetic compound. Br J Surg 66: 861–863, 1979.

    Article  PubMed  CAS  Google Scholar 

  232. Falk R, Makowka L, Nossal N, Falk J, Rotstein L, Fields J, Asculai S: Mechanism of increased antitumor immunity by a synthetic polymer. J Surg Res 28: 485–491, 1980.

    Article  PubMed  CAS  Google Scholar 

  233. Makowka L, Falk R, Nossal N, Rotstein L, Falk J: Activation of the immune system to control experimental neoplastic growth by NED-137. In: Augmenting agents in cancer therapy, Hersh E, Chirigos M, Mastrangelo M (eds). New York: Raven Press, 1981, pp 295–311.

    Google Scholar 

  234. Okamoto H, Shoin S, Koshimura S, Shimizu R: Studies on the anti-cancer and Streptolysin S-forming abilities of hemolytic streptococci: A review. Jap J Microbial 11: 323–331, 1967.

    CAS  Google Scholar 

  235. Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagaki Y: Tumor–inhibitory effect of a streptococcal preparation (NSC–B116209). Ca Chemo Rep 56: 9–17, 1972.

    CAS  Google Scholar 

  236. Hoshino A, Kato T, Amo H, Ohta K: Antitumor effects of OK-432 on resistant cell lines of Yoshida sarcoma and L-1210 leukemia. Chemotherapy 20: 598–602, 1972.

    Google Scholar 

  237. Aoki T, Kvedar JP, Hollis VW, Jr, Bushar GS: Brief communication: Streptococcus pyogenes preparation OK-432: Immunoprophylactic and immunotherapeutic effects on the incidence of spontaneous leukemia in AKR mice. JNCI 56: 687–690, 1976.

    PubMed  CAS  Google Scholar 

  238. Matsubara S, Suzuki F, Ishida N: Induction of Immune interferon in mice treated with a bacterial immunopotentiator, OK-432. Ca Imm Immunother 6: 41–45, 1979.

    Google Scholar 

  239. Osaki T, Hamada T, Kurimura T, Hiramo A, Hama S: Effect of streptococcal preparation (Picibanil) on interferon production in oral squamous cell carcinoma patients. Yonago Acta Medica 22: 100–105, 1979.

    Google Scholar 

  240. Oshimi K, Kano S, Takaku F, Okumura K: Augmentation of natural killer cell activity by a streptococcal preparation, OK-432. JNCI 65: 1265–1269, 1980.

    PubMed  CAS  Google Scholar 

  241. Uchida A, Micksche M: In vitro augmentation of natural killing activity by OK-432. Int J Immunopharmacol 3: 365–375, 1981.

    Article  PubMed  CAS  Google Scholar 

  242. Oshimi K, Wakasugi H, Seki H, Kano S: Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. Ca Imm Immunother 99: 187–191, 1980.

    Google Scholar 

  243. Wakasugi H, Oshimi K, Miyata M, Morioka Y: Augmentation of natural killer cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors. J Clin Imm 1: 154–162, 1981.

    Article  CAS  Google Scholar 

  244. Talmadge J, Fidler I: Personal communication.

    Google Scholar 

Download references

Authors
  1. Richard V. Smalley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cedric W. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen A. Sherwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert K. Oldham
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Cancer Institute, Frederick Cancer Research Facility, Frederick, Maryland, USA

    Ronald B. Herberman

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Smalley, R.V., Long, C.W., Sherwin, S.A., Oldham, R.K. (1983). Biological Response Modifiers: Current Status and Prospects as Anti-Cancer Agents. In: Herberman, R.B. (eds) Basic and Clinical Tumor Immunology. Cancer Treatment and Research, vol 14. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3873-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3873-4_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3875-8

  • Online ISBN: 978-1-4613-3873-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation